If you have been researching options for depression, anxiety, PTSD, or chronic pain and have come across the word ketamine, you are not alone. Over the past decade, ketamine has moved from the fringes of psychiatric research into mainstream medicine, backed by a growing body of clinical evidence and an FDA approval that has reshaped how clinicians approach treatment-resistant conditions. At Vantage Telehealth, we believe that curiosity about your options is the first step toward finding care that actually works. This blog is designed to give you an honest, science-grounded introduction to what ketamine therapy is, how it works, and what you should know before exploring it further.
What Is Ketamine?
Ketamine was first synthesized in 1962 and approved by the FDA in 1970 as an anesthetic agent. It has been used safely in surgical and medical settings for more than five decades, and it remains on the World Health Organization’s list of essential medicines. What makes ketamine distinctive among psychiatric treatments is its mechanism of action: it works through the glutamate system rather than the serotonin, dopamine, or norepinephrine pathways targeted by traditional antidepressants.
Glutamate is the brain’s primary excitatory neurotransmitter. Ketamine is an NMDA receptor antagonist, meaning it blocks a specific type of glutamate receptor. This blockade triggers a cascade of downstream effects, including a rapid surge in brain-derived neurotrophic factor (BDNF), a protein that promotes neuroplasticity, the brain’s capacity to form new neural connections. For people with depression and other mood disorders, this mechanism may explain ketamine’s most remarkable clinical property: it can produce meaningful symptom relief within hours of administration, a speed that no traditional antidepressant approaches.
How Ketamine Became a Mental Health Treatment
The scientific interest in ketamine’s psychiatric applications grew substantially in the early 2000s, when researchers published findings showing that ketamine produced rapid and robust reductions in depressive symptoms, even in patients who had failed multiple prior treatments. The 2006 study by Zarate and colleagues at the National Institute of Mental Health, published in the Archives of General Psychiatry, is often cited as a landmark: in that trial, a single infusion produced significant antidepressant effects within two hours and lasting up to a week in patients with treatment-resistant depression.
Subsequent research expanded our understanding of which conditions may respond to ketamine treatment. Evidence has accumulated for treatment-resistant depression (TRD), suicidal ideation, bipolar depression, PTSD, obsessive-compulsive disorder, and certain chronic pain conditions. The quality of evidence varies across conditions, and researchers continue to explore optimal protocols, frequency of treatment, and long-term maintenance strategies.
The FDA Approval: Esketamine (Spravato)
In 2019, the FDA approved esketamine (Spravato), a nasal spray form of a molecule closely related to ketamine, for treatment-resistant depression. This was a historic moment: the first genuinely new class of antidepressant approved in decades. In January 2025, the FDA expanded the Spravato indication to allow its use as a standalone treatment for TRD, a significant regulatory shift that acknowledged the robust clinical evidence for this approach. The approval requires administration in a certified healthcare setting with monitoring.
It is important to understand that Spravato (esketamine) and racemic ketamine (the original compound) are related but distinct. Research and clinical practice have involved both, and the treatment landscape continues to evolve. Your provider can help clarify which approach may be most appropriate for your situation, based on your clinical history, the nature of your symptoms, and your specific goals.
What Conditions May Benefit from Ketamine Therapy?
The clinical evidence is strongest for treatment-resistant depression, defined as depression that has not responded adequately to at least two antidepressant trials. For TRD, the data are compelling: multiple randomized controlled trials have shown significant symptom reduction, and for some patients, sustained remission. Ketamine has also shown promise for acute suicidal ideation, reducing suicidal thoughts more rapidly than standard treatments.
Beyond depression, research has examined ketamine for post-traumatic stress disorder (PTSD), with studies showing reductions in PTSD symptom clusters including re-experiencing, hyperarousal, and avoidance. Early research in OCD has shown mixed but promising results. Chronic pain conditions, particularly those involving central sensitization, represent another area of active investigation. It is important to approach the evidence for each condition with appropriate context: your provider at Vantage can discuss what the research specifically shows in the context of your medical history.
The Role of Integration
Many clinicians who specialize in ketamine therapy emphasize that the treatment is most effective when paired with supportive psychotherapy, often called integration therapy. Integration refers to the process of making psychological sense of the experiences and insights that may arise during or after ketamine treatment, and translating them into lasting behavioral and cognitive changes. While ketamine can create a window of increased neuroplasticity, integration therapy aims to use that window intentionally. The specific format of integration support is determined on an individual basis and discussed with your provider during your clinical evaluation.
What Ketamine Therapy Is Not
It is worth stating clearly what ketamine therapy is not. It is not a recreational experience, it is not a cure for all mental health conditions, and it is not appropriate for everyone. Ketamine is a Schedule III controlled substance that requires proper medical evaluation, screening for contraindications, and ongoing clinical oversight. There are meaningful differences between clinics that provide comprehensive, evidence-based care with appropriate integration support and those that provide minimal clinical oversight. The quality of your care and the qualifications of your provider matter enormously.
At Vantage Telehealth, every patient interested in ketamine therapy begins with a thorough clinical evaluation by a licensed provider. Appropriateness for treatment is determined individually, based on your complete medical and psychiatric history. This evaluation process is not a formality; it is a genuine clinical safeguard designed to ensure that any treatment you receive is the right treatment for you.
Is Ketamine Therapy Right for You?
The best way to answer that question is through a clinical conversation. If you have been living with depression, PTSD, or another condition that has not responded adequately to standard treatments, and you are curious about what your options might be, Vantage Telehealth offers a straightforward path to that conversation. Our intake process begins with a brief online form that helps your provider understand your history and goals. From there, a licensed clinician will guide you through the evaluation process with transparency, expertise, and genuine care. You do not need to have all the answers before reaching out. That is exactly what the evaluation is for.
Learn more about ketamine-assisted therapy at Vantage
Frequently Asked Questions
What is ketamine-assisted therapy?
Ketamine-assisted therapy is a treatment that combines clinically supervised, low-dose ketamine with structured psychotherapy or integration sessions. It is used to treat conditions such as treatment-resistant depression, PTSD, and severe anxiety. The medication is prescribed by a licensed provider following a comprehensive evaluation.
How does ketamine therapy differ from traditional antidepressants?
Traditional antidepressants like SSRIs typically take four to eight weeks to reach full effect and work primarily by modulating serotonin. Ketamine acts on the glutamate system and often produces measurable symptom improvement within hours to days. It is generally reserved for people who have not responded to first-line treatments.
What conditions does ketamine therapy treat?
Clinical research supports ketamine’s use for treatment-resistant depression, PTSD, and certain anxiety and mood disorders that have not responded to standard treatments. It may also help patients with acute suicidal ideation as part of a supervised care plan. It is not a first-line treatment and always requires clinical evaluation.
Is ketamine therapy safe?
When prescribed and monitored by a licensed provider, low-dose ketamine used therapeutically has a well-established safety profile. Common side effects can include mild dissociation, elevated blood pressure, or nausea during the session. Vantage’s telehealth model includes provider screening, medical history review, and structured follow-up to support safe use.
How quickly does ketamine therapy work compared to SSRIs?
Many patients report noticeable mood improvement within 24 to 72 hours of their first ketamine session, compared with the four-to-eight-week timeline typical for SSRIs. Response is not universal, and sustained benefit generally requires a series of sessions plus integration work. Individual response is assessed at each follow-up.
Who is a good candidate for ketamine treatment?
Good candidates typically include adults with treatment-resistant depression, PTSD, or another qualifying condition who have not responded to at least one or two standard treatments. Candidates are medically stable, screened for contraindications such as uncontrolled hypertension or a history of psychosis, and willing to participate in integration therapy. A licensed provider in our partner medical network makes this determination during the initial evaluation.
See how Vantage Telehealth can help — Get Started →
Disclaimer: This content is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment recommendation. Ketamine is a Schedule III controlled substance and its use for mental health conditions must be supervised by a qualified medical provider. Clinical appropriateness for ketamine therapy is determined on an individual basis by your provider. If you are experiencing a mental health crisis or thoughts of suicide, please call or text 988 (Suicide and Crisis Lifeline), call 911, or go to your nearest emergency room. The information presented here reflects general educational content and may not apply to your specific situation. Always consult a licensed healthcare professional before starting any new treatment.